<DOC>
	<DOC>NCT00002190</DOC>
	<brief_summary>To explore the antiviral efficacy, tolerability and safety of saquinavir plus zidovudine plus lamivudine.</brief_summary>
	<brief_title>A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients</brief_title>
	<detailed_description>A total of 30 patients receive the triple drug regimen saquinavir plus zidovudine plus lamivudine until the completion of the analysis after at least 4 weeks of therapy.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<criteria>Inclusion Criteria Patients must have: HIV antibody positive. CD4 count &gt;= 150 and &lt;= 500 cells/mm3. Exclusion Criteria Prior Medication: Excluded: Prior antiretroviral therapy. Prior protease inhibitor therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 1997</verification_date>
	<keyword>Drug Therapy, Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Saquinavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>